Jill Lacy MD
Professor of Medicine (Medical Oncology)
Departments & Organizations
Yale Medical Group
Office of Student ResearchCancer Center, Yale: Brain Tumor Center; Gastrointestinal Cancer Program; Developmental Therapeutics; Sarcoma Oncology ProgramMedical OncologyDevelopmental Therapeutics
Clinical research in gastrointestinal malignancies; Gastroesphageal, pancreatic, and colorectal cancers; Brain tumors; Epstein-Barr virus-associated malignancies more...
- M.D., Yale University, 1978
- Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M,?Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. Cancer J 13:257-62, 2007
- Srimatkandada P, Loomis R, Carbone R, Srimatkandada S, Lacy J. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases. Eur J Haematol. 2008 May;80(5):407-18. Epub 2008 Jan 23.
- Mayer, T, Lacy, J, Baehring, J. A single institution’s experience with bevacizumab in combination with cytotoxic chemotherapy in progressive malignant glioma. Clinical Medicine: Oncology 2: 455-459, 2008